GlassScriptPhysician profile
Safwat B Sharobeem
NPI 1518941780
$1,816.67
in general payments reported to CMS, 2019-2025
9 companies · $636 in 2025
The $636 reported for 2025 was more than what 92% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $45.93 · 2021: $142 · 2022: $58.97 · 2023: $266 · 2024: $250 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652 · Honoraria: $450 · Education: $50.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.64 |
| Honoraria | $450.00 |
| Education | $50.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $466.46 | 2022-2025 | Cleviprex, Kengreal |
| Becton, Dickinson and Company | $450.00 | 2025 | |
| Merck Sharp & Dohme LLC | $357.33 | 2019-2025 | Bridion |
| Mallinckrodt Enterprises LLC | $287.94 | 2019 | |
| Heron Therapeutics, INC. | $89.85 | 2021 | |
| Fisher & Paykel Healthcare INC | $66.91 | 2023-2025 | Fisher & Paykel Healthcare |
| Edwards Lifesciences Corporation | $64.22 | 2024 | Hemosphere |
| Pacira Pharmaceuticals Incorporated | $18.36 | 2022 | |
| Mallinckrodt Hospital Products INC. | $15.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Safwat Sharobeem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.